Skip to Content
Merck
CN

SML3602

Pipobroman

≥98% (HPLC)

Synonym(s):

1,​1′-​(1,​4-​Piperazinediyl)​bis[3-​bromo-1-​propanone, 1,​4-​bis(3-​Bromo-​1-​oxopropyl)​-piperazine, N,N-Bis-(3-bromopropionyl)-piperazine, NSC-​25154

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C10H16Br2N2O2
CAS Number:
54-91-1
Molecular Weight:
356.05
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD00866372

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Pipobroman, ≥98% (HPLC)

SMILES string

BrCCC(=O)N1CCN(CC1)C(=O)CCBr

InChI

1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2

InChI key

NJBFOOCLYDNZJN-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Anti-cancer drug, cytostatic alkylating agent
Pipobroman is an alkylating agent that is used as anti-cancer drug. It also has clinical activity in polycythemia vera and thrombocythemia.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000230089
0000230088
0000230089
0000230088

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Giovanni Fazio et al.
Journal of thrombosis and thrombolysis, 35(2), 282-285 (2012-07-31)
Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by an abnormal increase in red blood cells. The involvement of the heart during the course of the illness represents a common cause of morbidity and it is linked to an
Jean-Jacques Kiladjian et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(29), 3907-3913 (2011-09-14)
The overall impact of hydroxyurea (HU) or pipobroman treatments on the long-term outcome of patients with polycythemia vera (PV) has not been assessed in randomized studies. We report final analyses from the French Polycythemia Study Group (FPSG) study, which randomly

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service